Related Experiment Videos
Does 99mTc-sestamibi uptake discriminate breast tumors?
Anne Cayre1, Florent Cachin, Jean Maublant
1Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, France. Anne.Cayre@cjp.fr
Cancer Investigation
|November 30, 2004
Summary
99mTc-sestamibi scintimammography (SMM) uptake in breast tumors correlates with histopathology and prognosis. High SMM uptake indicates aggressive features and poorer survival, while low uptake suggests a better outlook.
Area of Science:
- Nuclear Medicine
- Oncology
- Pathology
Background:
- 99mTc-sestamibi scintimammography (SMM) is a diagnostic tool for breast tumors.
- Understanding the relationship between SMM uptake and tumor characteristics is crucial for prognosis.
Purpose of the Study:
- To investigate the correlation between 99mTc-sestamibi uptake and histopathological features of breast tumors.
- To assess the prognostic value of SMM uptake in breast cancer patients.
Main Methods:
- 101 breast tumors from 98 patients underwent static 99mTc-sestamibi scintimammography.
- Tumor uptake was scored and classified as low or high.
- Histopathological characteristics were determined via biopsy, including Scarff-Bloom and Richardson (SBR) grade, axillary involvement, tumor size, and estrogen receptor status.
Main Results:
- 99mTc-sestamibi uptake positively correlated with SBR grade, axillary involvement, and tumor size (p < 0.0005).
- Uptake negatively correlated with estrogen receptors (p < 0.001).
- Invasive lobular carcinoma showed lower uptake than invasive ductal carcinoma (p < 0.01).
- Low SMM uptake was associated with a higher five-year survival rate (p < 0.005).
Conclusions:
- 99mTc-sestamibi uptake effectively discriminates breast tumors with varying histopathological characteristics.
- SMM uptake serves as a significant independent prognostic factor for breast cancer, predicting survival outcomes.